FROM AWARD-WINNING AUTHOR DR GOVIND SHUKLA, NUTRITION EXPERT

Govind Shukla, Specializes in Pharmacology, Toxicology, Nutraceuticals & Herbal Drugs has published More than 100 research papers in National & International Journals. He is also a reviewer of International Journal of Pharmacology & pharmacotherapeutics, Chief editor of IJPNR Journal & Freelance Medical Writer for Different publication Groups including Lambert Academic Publishing Saarbrucken, Germany.

LACTO-D3 Sachets  The sunshine Vitamin provides VitaminD3 optimum Strength

Supplementation of  cholecalciferol (vitaminD3) in Lacto-D3 sachets significantly reduces all cause mortality emphasizes the  medical, ethical, and legal implications of promptly diagnosing  and adequately treating VitamnD3 deficiency. Not only are such deficiencies common, and probably the rule, VitamnD3  deficiency is implicated in most of the diseases of civilization.  VitamnD3’s final metabolic product is a potent, pleiotropic, repair  and maintenance, seco-steroid hormone that targets more than 200 human genes in a wide variety of tissues, meaning it has  as many mechanisms of action as genes it targets. One of the  most important genes VitamnD3 up-regulates is for cathelicidin,  a naturally occurring broad-spectrum antibiotic. Natural VitamnD3 levels, those found in humans living in a sun-rich environment,  are between 40-70 ng/mL, levels obtained by few modern  humans. Assessing serum 25-hydroxy-VitamnD3(25(OH)D) is  the only way to make the diagnosis and to assure treatment  is adequate and safe. Three treatment modalities exist for  VitamnD3 deficiency: sunlight, artificial ultraviolet B (UVB)  radiation, and VitamnD3 supplementation. Treatment of vitamin  D deficiency in otherwise healthy patients with 2,000-7,000  IU VitamnD3  per day should be sufficient to maintain yearround 25(OH)D levels between 40-70 ng/mL. In those with  serious illnesses associated with VitamnD3 deficiency, such  as cancer, heart disease, multiple sclerosis, diabetes, autism,  and a host of other illnesses, doses should be sufficient to maintain year-round 25(OH)D levels between 55-70 ng/ mL. VitamnD3-deficient patients with serious illness should  not only be supplemented more aggressively than the well,  they should have more frequent monitoring of serum 25(OH) D and serum calcium. VitamnD3 should always be adjuvant treatment in patients with serious illnesses and never replace  standard treatment. Theoretically, pharmacological doses  of VitamnD3 (2,000 IU/kg/day for three days) may produce  enough of the naturally occurring antibiotic cathelicidin to cure  common viral respiratory infections, such as influenza and common cold.

Share This